BioSpace News Archive

Shanghai Yingli Pharmaceuticals Ltd, a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association being held June 9-17, 2021.

Ipsen announced findings from a new U.S. healthcare database analysis to assess the current treatment patterns of adults living with spasticity in a real-life setting.

Genentech, a member of the Roche Group, announced new interim data from two studies of Evrysdi® ; JEWELFISH and RAINBOWFISH.

Synthetic biology market has evolved on the back of surging industry interest worldwide on the profound capabilities it is said to possess, mainly by virtue of redesigning biological components and systems.

Transparency Market Research has published a new report titled ‘Surgery Tables Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the new report, the global surgery tables market was valued at above US$ 700 Mn, in terms of revenue, and stood at over 45,000 units, in terms of volume, in 2017.

The drive for molecular biology enzymes, kits and reagents, stems from steady strides being made in life sciences industry.

Transparency Market Research has published a new report titled, “Medical Imaging Phantoms Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Transparency Market Research has published a new report titled, “Endoscopic Stricture Management Device Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The needles that are used during aspiration and biopsy procedure have been gaining traction in the recent years. The market is competitive with the presence of many market players; each of them jostling with each other to expand the presence in the global aspiration and biopsy needles market.

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announces that it has entered into an exclusive, worldwide license agreement with SATT Conectus for the development and commercialization of a gene therapy candidate for the treatment of Fragile X syndrome.